Search
EDI-200
go.drugbank.com/drugs/DB18188InvestigationalEDI-200 is a fusion protein consisting of human immunoglobim G1 constant region Fc region fused to the human receptor binding domain of ectodysplasin-A1.
Brazikumab
go.drugbank.com/drugs/DB16115InvestigationalBrazikumab is under investigation in clinical trial NCT03759288 (An Active and Placebo-controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease).
HKI-357
go.drugbank.com/drugs/DB13002InvestigationalHki 357 is under investigation in clinical trial NCT00550381 (Study Evaluating the Safety, Tolerability, and Pharmacokinetics (PK) of HKI-357 Administered Orally to Healthy Subjects).
Lunsekimig
go.drugbank.com/drugs/DB19009InvestigationalLunsekimig is under investigation in clinical trial NCT06102005 (Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma).
Deudomperidone
go.drugbank.com/drugs/DB19055InvestigationalDeudomperidone is under investigation in clinical trial NCT05832151 (A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis).
p-Boronophenylalanine
go.drugbank.com/drugs/DB19158Investigationalp-Boronophenylalanine is under investigation in clinical trial NCT00039572 (Boron Neutron Capture Therapy in Treating Patients With Glioblastoma Multiforme or Melanoma Metastatic to the Brain).
Padsevonil
go.drugbank.com/drugs/DB14977InvestigationalPadsevonil is under investigation in clinical trial NCT03695094 (A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil).
Imidacloprid
go.drugbank.com/drugs/DB11421ExperimentalVet approvedImidacloprid is a patented chemical, Imidacloprid is manufactured by Bayer Cropscience (part of Bayer AG) and sold under trade names Kohinor, Admire, Advantage, Gaucho, Merit, Confidor, Hachikusan, Premise
LV-SMENP Vaccine
go.drugbank.com/drugs/DB15804ExperimentalLV-SMENP-DC is a vaccine candidate being developed by Shenzhen Geno-Immune Medical Institute that comprises dendritic cells that are modified with lentiviral vector-expressing synthetic minigene which … This vaccine is also administered with antigen-specific cytotoxic T lymphocytes (CTLs). As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials.
Urelumab
go.drugbank.com/drugs/DB12077InvestigationalThe antibody product was developed using Medarex's UltiMAb(R) technology and was the first UltiMAb- derived antibody in clinical development by Bristol-Myers Squibb under the December 2003 agreement with